Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24926328 | 1.00 | CNR1 (0.34) | CNR1CNR2SIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL9891858 | 1.00 | CNR1 (0.34) | CNR1CNR2SIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL24926685 | 1.00 | CNR1 (0.34) | CNR1CNR2SIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL24926337 | 0.98 | CNR1 (0.33) | CNR1CNR2 | |
| SCHEMBL9891857 | 0.98 | CNR1 (0.33) | CNR1CNR2 | |
| SCHEMBL16253050 | 0.93 | CNR2 (0.33) | CNR1CNR2 | |
| SCHEMBL9891856 | 0.93 | CNR1 (0.33) | CNR1CNR2 | |
| SCHEMBL16253057 | 0.91 | CNR1 (0.32) | CNR1CNR2 | |
| SCHEMBL2689915 | 0.91 | CNR1 (0.32) | CNR1CNR2 | |
| SCHEMBL9891855 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | CNR1 4784/4885CNR2 4800/4885SIGMAR1 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.